G V Papatheodoridis

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. ncbi request reprint Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sofias Avenue, Athens 11527, Greece
    Curr Opin Mol Ther 8:352-7. 2006
  2. ncbi request reprint High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity
    George V Papatheodoridis
    Hellenic Foundation for Gastroenterology and Nutrition, Athens, Greece
    Eur J Gastroenterol Hepatol 19:281-7. 2007
  3. doi request reprint Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    Hepatology 48:1451-9. 2008
  4. pmc Elastography for hepatic fibrosis severity in chronic hepatitis B or C
    Maria Vasiliki Papageorgiou
    2nd Department of Internal Medicine, Medical School of Athens University, Athens, Greece
    Case Rep Gastroenterol 5:63-72. 2011
  5. doi request reprint Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
    George Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration Hospital of Athens, Greece Academic Department of Gastroenterology, Athens University Medical School, Laikon Hospital of Athens, Greece Electronic address
    J Hepatol 60:62-8. 2014
  6. doi request reprint Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School Hippokration General Hospital of Athens, Athens, Greece
    Liver Int 33:151-6. 2013
  7. doi request reprint Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Greece
    J Hepatol 57:196-202. 2012
  8. doi request reprint Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital of Athens, Athens, Greece
    J Viral Hepat 15:434-41. 2008
  9. doi request reprint Current management of hepatitis B virus infection before and after liver transplantation
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas Sophias Avenue, Athens, Greece
    Liver Int 29:1294-305. 2009
  10. ncbi request reprint Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    J Hepatol 51:931-8. 2009

Collaborators

Detail Information

Publications88

  1. ncbi request reprint Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sofias Avenue, Athens 11527, Greece
    Curr Opin Mol Ther 8:352-7. 2006
    ..In April 2003, phase II trials were initiated, the results of which were reported in February 2006. LB-80380 is the prodrug of LB-80317 (PMCDG), another compound from this series...
  2. ncbi request reprint High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity
    George V Papatheodoridis
    Hellenic Foundation for Gastroenterology and Nutrition, Athens, Greece
    Eur J Gastroenterol Hepatol 19:281-7. 2007
    ....
  3. doi request reprint Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    Hepatology 48:1451-9. 2008
    ..025). All inactive carriers had HBV DNA <20,000 IU/mL. Histological indication for treatment was present in 17% (6/35) of inactive carriers always due to moderate (stage 2) fibrosis without active necroinflammation...
  4. pmc Elastography for hepatic fibrosis severity in chronic hepatitis B or C
    Maria Vasiliki Papageorgiou
    2nd Department of Internal Medicine, Medical School of Athens University, Athens, Greece
    Case Rep Gastroenterol 5:63-72. 2011
    ..To assess the value of transient elastography for predicting significant fibrosis or cirrhosis in chronic hepatitis B or C (CHB or CHC) patients...
  5. doi request reprint Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
    George Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration Hospital of Athens, Greece Academic Department of Gastroenterology, Athens University Medical School, Laikon Hospital of Athens, Greece Electronic address
    J Hepatol 60:62-8. 2014
    ..We evaluated the changes of HBsAg and interferon-inducible protein 10 (IP10) serum levels in HBeAg-negative CHB patients treated with entecavir...
  6. doi request reprint Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School Hippokration General Hospital of Athens, Athens, Greece
    Liver Int 33:151-6. 2013
    ..Novel therapeutic options are needed to increase the rates of HBsAg loss and sustained off-treatment responses...
  7. doi request reprint Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Greece
    J Hepatol 57:196-202. 2012
    ..We systematically reviewed all the available histological data on HBeAg-negative patients with persistently normal ALT (PNALT) to determine the prevalence of significant liver disease and its associating factors...
  8. doi request reprint Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital of Athens, Athens, Greece
    J Viral Hepat 15:434-41. 2008
    ..Approximately 20% of HBeAg-negative CHB patients have HBV DNA <20 000 IU/mL with fluctuations >1 log(10) occurring in many of them...
  9. doi request reprint Current management of hepatitis B virus infection before and after liver transplantation
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas Sophias Avenue, Athens, Greece
    Liver Int 29:1294-305. 2009
    ..Monoprophylaxis with one of the new anti-HBV agents might be possible, particularly in patients preselected as having a low risk of HBV recurrence, but further data are needed and strategies to ensure compliance must be used...
  10. ncbi request reprint Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    J Hepatol 51:931-8. 2009
    ..We evaluated the prevalence of thrombotic risk factors (RFs) in non-alcoholic fatty liver disease (NAFLD) and their possible association with fatty liver or NASH...
  11. doi request reprint Review article: novel therapeutic options for chronic hepatitis C
    E Cholongitas
    Department of Internal Medicine, General Hospital of Sitia, Sitia, Greece
    Aliment Pharmacol Ther 27:866-84. 2008
    ..The efficacy of treatment against hepatitis C virus has improved, but it is still far from ideal. Thus, new antihepatitis C virus therapies are required...
  12. doi request reprint Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Athens, Greece
    J Hepatol 53:348-56. 2010
    ..The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues...
  13. doi request reprint Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece c
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Gut 60:1109-16. 2011
    ..To evaluate the risk and predictors of hepatocellular carcinoma (HCC) in HBeAg-negative chronic hepatitis B patients of the large HEPNET.Greece cohort study who received long-term oral antivirals starting with lamivudine monotherapy...
  14. doi request reprint Resistance issues in treating chronic hepatitis B
    George V Papatheodoridis
    Athens University Medical School, 2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Athens, Greece
    Future Microbiol 3:525-38. 2008
    ..Combination of two agents without cross-resistance should be used in any patient with HBV resistance...
  15. ncbi request reprint Therapeutic strategies in the management of patients with chronic hepatitis B virus infection
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University School of Medicine, Hippokration General Hospital of Athens, Athens, Greece
    Lancet Infect Dis 8:167-78. 2008
    ..Entecavir resistance is rare in naive individuals (year 4, <1%), but increases over time in lamivudine-resistant patients (year 4, 43%). The best strategy for long-term therapy in chronic HBV infection has yet to be established...
  16. doi request reprint Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease
    George V Papatheodoridis
    Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sophias Ave, 115 27 Athens, Greece
    J Clin Gastroenterol 44:e87-95. 2010
    ..Apoptotic caspases are substantially activated in liver and serum caspase activity has been suggested as a marker of early liver injury...
  17. ncbi request reprint Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review
    George V Papatheodoridis
    Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, 114 Vas Sophias Avenue, 115 27 Athens, Greece
    Clin Gastroenterol Hepatol 4:130-42. 2006
    ..The aim was to systematically review the interactions between Helicobacter pylori (HP) infection and NSAID use on the risk of uncomplicated or bleeding peptic ulcer...
  18. doi request reprint Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    Liver Int 31:95-103. 2011
    ..Because there will always be concerns for safety and family planning issues with long-term therapy, NUCs should be used judiciously and should not be prescribed in young CHB patients with mild liver disease...
  19. ncbi request reprint Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection
    G V Papatheodoridis
    Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sophias Ave, 115 27 Athens, Greece
    Gut 57:500-6. 2008
    ..Patients/..
  20. doi request reprint A Greek survey of community prevalence and characteristics of constipation
    George V Papatheodoridis
    Hellenic Foundation for Gastroenterology and Nutrition, 30 P Ioakim Street, Athens, Greece
    Eur J Gastroenterol Hepatol 22:354-60. 2010
    ..We evaluated the prevalence and the main characteristics of constipation in the Greek general population...
  21. doi request reprint Ethics related to liver biopsies and antiviral therapies in chronic viral hepatitis
    George V Papatheodoridis
    2nd Department of Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Dig Dis 26:59-65. 2008
    ....
  22. ncbi request reprint Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis
    G V Papatheodoridis
    Academic Department of Internal Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 13:303-10. 2006
    ..The presence of diabetes is strongly associated with more severe liver fibrosis, but such an association may be related to the high prevalence of diabetes in patients with cirrhosis...
  23. ncbi request reprint Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C
    E Tsochatzis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas Sophias Ave, 11527 Athens, Greece
    Dig Liver Dis 39:936-42. 2007
    ..We investigated the prevalence of and the parameters associated with steatosis in HBeAg-negative chronic hepatitis B...
  24. ncbi request reprint A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B
    E K Manesis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 23:99-106. 2006
    ..Treatment of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-) with interferon or lamivudine alone is inefficient and reports of combination treatment with both drugs, equivocal so far...
  25. ncbi request reprint Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis
    E Tsochatzis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 27:80-9. 2008
    ..The prevalence of metabolic syndrome and its possible impact on the severity of liver histological lesions have not been studied prospectively in chronic liver diseases...
  26. ncbi request reprint Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration Hospital of Athens, Greece
    J Viral Hepat 12:199-206. 2005
    ..In relapsers and nonresponders, fibrosis benefit equals the treatment period. The strongest factor associated with fibrosis progression is the change in necroinflammatory activity...
  27. ncbi request reprint Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments
    V Sypsa
    Department of Hygiene and Epidemiology, Athens University Medical School, Athens, Greece
    J Viral Hepat 12:543-50. 2005
    ..Intensive primary prevention efforts coupled with increased access to the currently available treatments are necessary to control the chronic consequences of HCV epidemic...
  28. doi request reprint Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection
    D Vassilopoulos
    2nd Department of Medicine, Hippokration General Hospital, Athens University School of Medicine, 114 Vass Sophias Avenue, Athens 115 27, Greece
    Ann Rheum Dis 69:1352-5. 2010
    ..The aim of this prospective study was to examine the safety of anti-tumour necrosis factor (TNF) therapy in patients with rheumatic disease and hepatitis B virus (HBV) infection...
  29. doi request reprint Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study
    E Tsochatzis
    2nd Department of Internal Medicine, Hippokration General Hospital, University of Athens, Athens, Greece
    Aliment Pharmacol Ther 30:947-54. 2009
    ..Chronic hepatitis C (CHC) induces insulin resistance (IR) and subsequently diabetes...
  30. ncbi request reprint Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
    George V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Hepatology 36:219-26. 2002
    ..ALT activity peaks close to the onset of biochemical breakthrough, decreasing thereafter but remaining persistently abnormal with fluctuating levels...
  31. doi request reprint The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre
    Ioannis P Giannousis
    Second Department of Internal Medicine, Athens University Medical School, Hipppokration General Hospital, Athens 115 27, Greece
    Eur J Gastroenterol Hepatol 22:172-9. 2010
    ..To investigate the burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre...
  32. ncbi request reprint Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era
    George V Papatheodoridis
    2nd Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Am J Transplant 3:250-8. 2003
    ..All these advances in anti-HBV therapy have made HBV liver disease an indication for liver transplantation irrespective of viral replication status, a complete turn around from 10 years ago...
  33. ncbi request reprint The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Hepatol 34:306-13. 2001
    ..Therefore, long-term biochemical remission appears to represent a satisfactory therapeutic target in this setting...
  34. doi request reprint Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C
    E Tsochatzis
    2nd Department of Internal Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 17:800-6. 2010
    ..The previously mentioned observations suggest a viral effect on hepatic hepcidin production, but might also support its involvement in the inflammatory process...
  35. doi request reprint Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study
    E K Manesis
    Liver Unit, Euroclinic, Athens, Greece
    Aliment Pharmacol Ther 29:1121-30. 2009
    ..The effect of such treatments on the natural course of CHC has been evaluated in small clinical trials with conflicting results...
  36. ncbi request reprint Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine
    George V Papatheodoridis
    2nd Academic Department of Internal Medicine, Hippokration General Hospital of Athens, Greece
    Hepatology 42:121-9. 2005
    ..In such patients with advanced fibrosis, close follow-up for lamivudine resistance and prompt onset of additional antiviral therapy is required or the ab initio use of agent(s) with low resistance rates should be considered...
  37. ncbi request reprint Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load
    A Katsoulidou
    Department of Hygiene and Epidemiology, Athens University Medical School, Athens, Greece
    Vox Sang 92:8-14. 2007
    ..The main objective of the study was to assess the analytical and clinical sensitivity of the multiplex and discriminatory probe assays in samples with a low viral load...
  38. ncbi request reprint Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
    S J Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Hepatology 32:847-51. 2000
    ..However, response rates tend to decrease with time and breakthroughs due to YMDD mutants accumulate. ALT activity during breakthroughs often exceeds the baseline and may reach even acute hepatitis levels...
  39. ncbi request reprint Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 11:287-96. 2004
    ....
  40. pmc Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis
    G V Papatheodoridis
    Hippokration General Hospital, Athens, Greece
    Gut 52:404-9. 2003
    ..Thrombosis of the small intrahepatic veins has been suggested to trigger liver tissue remodelling. We evaluated the prevalence of multiple thrombotic risk factors and their association with the extent of fibrosis in chronic viral hepatitis...
  41. ncbi request reprint Diagnosis and management of pre-core mutant chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 8:311-21. 2001
    ..Several other antiviral agents are currently being evaluated in this setting with combined regimens being the most reasonable step for the near future...
  42. ncbi request reprint Treatment of HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Semin Liver Dis 23:81-8. 2003
    ..Many other antiviral agents and immunomodulatory approaches are currently evaluated for CHB, but, besides IFN-alpha, none has yet been convincingly shown to induce sustained off-therapy responses...
  43. doi request reprint Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study
    A Mavrogiannaki
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 16:430-6. 2009
    ..An OGTT might be necessary at the baseline work-up of CHB or CHC patients, as a normal fasting glucose value does not exclude IGT or OGTT-diabetes...
  44. ncbi request reprint Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis
    Nikolaos V Chrysanthos
    2nd Department of Internal Medicine, Medical School of Athens University, Athens, Greece
    Eur J Gastroenterol Hepatol 18:389-96. 2006
    ..We assessed the value of the recently developed aspartate aminotransferase to platelet ratio index (APRI) for predicting significant fibrosis or cirrhosis in patients with chronic hepatitis C or HBeAg-negative chronic hepatitis B...
  45. ncbi request reprint The evolving role of leptin and adiponectin in chronic liver diseases
    Emmanuel Tsochatzis
    2nd Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 101:2629-40. 2006
    ....
  46. ncbi request reprint Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance
    George V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 97:1618-28. 2002
    ..To date, there is no proven effective therapy for the resistant HBV mutant strains, although adefovir and entecavir seem to be interesting candidates...
  47. ncbi request reprint Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity
    Emmanuel Tsochatzis
    Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Scand J Gastroenterol 43:1128-36. 2008
    ..The objective of this study was to investigate serum levels of the above three adipokines in relation to the etiology of liver disease and to determine their associations with histological severity...
  48. ncbi request reprint Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others)
    Stephanos J Hadziyannis
    Department of Medinine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, Athens, Greece
    J Hepatol 39:S172-6. 2003
  49. doi request reprint Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications
    Emmanuel A Tsochatzis
    Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Scand J Gastroenterol 44:6-14. 2009
    ..As specific therapies do not exist, patients with metabolic syndrome and CHC and NAFLD should be counseled to lose weight and ameliorate their glycemic control and lipid profile...
  50. ncbi request reprint Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection
    Emanuel K Manesis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 98:2261-7. 2003
    ..We evaluated the clinical significance of a single baseline serum HBV DNA measurement by a quantitative polymerase chain reaction (PCR) assay in this setting...
  51. ncbi request reprint Review article: current management of chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 19:25-37. 2004
    ..Adefovir is also effective against lamivudine-resistant strains. Many other anti-viral agents, immunomodulatory approaches and combination therapies are currently being evaluated in chronic hepatitis B...
  52. pmc Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy
    Emmanuel A Tsochatzis
    2nd Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
    Mediators Inflamm 2009:831670. 2009
    ..We also comment on their potential use as noninvasive markers for differentiating simple fatty liver from NASH as well as on their potential future therapeutic role in patients with NASH...
  53. doi request reprint Changes of liver and muscle enzymes activity in patients with rigor
    Nikolaos Sevastos
    2nd Department of Internal Medicine, National University of Athens Medical School, Hippokration General Hospital, 114 Vas Sophias Ave, 11527 Athens, Greece
    Eur J Intern Med 19:109-14. 2008
    ..We investigated whether changes of liver and muscle enzymes activity are associated with rigor of several causes and have any prognostic significance...
  54. doi request reprint Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C
    Spilios Manolakopoulos
    2nd Academic Department of Internal Medicine, Hippokration General Hospital, Agia Paraskevi, Athens, Greece
    Liver Int 30:1454-60. 2010
    ..We analysed the effect of IDU and/or substitution therapy on chronic hepatitis C (CHC) treatment adherence and response...
  55. ncbi request reprint Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis
    Melanie Deutsch
    Academic Department of Internal Medicine Hippocration General Hospital, Athens, Greece
    Eur J Gastroenterol Hepatol 20:5-9. 2008
    ..In contrast, extrahepatic malignancies have been reported to be significantly associated with PBC. The aim of this study was to determine the incidence of HCC and of extrahepatic malignancies in a large cohort of patients with PBC...
  56. ncbi request reprint Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors
    Emmanuel Tsochatzis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 102:634-41. 2007
    ..We determined the parameters associated with steatosis in 350 chronic hepatitis C patients, focusing on genotype 4...
  57. ncbi request reprint Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude
    Nikolaos Sevastos
    Second Department of Internal Medicine, National University of Athens Medical School, Sotiria Hospital, Athens, Greece
    J Lab Clin Med 147:139-44. 2006
    ..However, the degree of pseudohyperkalemia does not increase proportionally with the increase of platelet counts, which may be associated with transfer of part of potassium load from the plasma back into red and white blood cells...
  58. ncbi request reprint Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 15:689-98. 2001
    ..Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non-sustained responders...
  59. ncbi request reprint Hepatobiliary and pancreatic: spontaneous splenorenal shunts in portal hypertension
    E Tsochatzis
    Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Greece
    J Gastroenterol Hepatol 21:1214. 2006
  60. ncbi request reprint Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Semin Liver Dis 26:130-41. 2006
    ..Combination therapy with adefovir added to LMV in LMV-resistant patients is extremely effective; cases of adefovir-resistance have not been reported to date...
  61. ncbi request reprint Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs
    George V Papatheodoridis
    Academic Department of Medicine, Henry Dunant Hospital, Athens, Greece
    Am J Med 116:601-5. 2004
    ....
  62. doi request reprint Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B
    Emmanuel Tsochatzis
    Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece
    Scand J Gastroenterol 44:752-9. 2009
    ..The purpose of this study was to evaluate the relationship, if any, of such factors on liver fibrosis in a cohort of patients with CHB and CHC...
  63. ncbi request reprint The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection
    G V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Athens, Greece
    J Viral Hepat 21:517-24. 2014
    ..5 kPa and 50% of carriers with LSM > 6.5 kPa and HBV-DNA > 2000 IU/mL. ..
  64. ncbi request reprint Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment
    E Tsochatzis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Greece
    Dig Liver Dis 39:490-4. 2007
    ..However, its exact role in this setting needs to be evaluated within well-designed, controlled clinical trials...
  65. ncbi request reprint Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban general population
    G V Papatheodoridis
    Medical School of Athens University, Hellenic Foundation for Gastroenterology and Nutrition, Athens, Greece
    Scand J Gastroenterol 40:412-21. 2005
    ..To study the prevalence of gastrointestinal symptoms in the Greek urban general population, their associations with patient characteristics, and their effect on patients' daily activities...
  66. ncbi request reprint Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users
    George V Papatheodoridis
    Second Academic Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital of Athens, 114 Vas Sophias Ave, Athens 115 27, Greece
    World J Gastroenterol 11:3811-6. 2005
    ..In contrast, testing for H pylori or PPI therapy is not recommended for chronic NSAID/aspirin users with no ulcer complications or those at a low risk of complications...
  67. ncbi request reprint Simultaneous diagnosis of ulcerative jejunoileitis and coeliac disease in an elderly man
    Konstantinos Koutroutsos
    2nd Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
    Digestion 73:20-4. 2006
    ....
  68. ncbi request reprint Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?
    Evangelos Cholongitas
    Second Department of Internal Medicine, Hippokration General Hospital of Athens, University of Athens School of Medicine, Greece
    J Gastroenterol Hepatol 21:581-7. 2006
    ..The aim of this study is to evaluate the association between the use of propranolol and development of spontaneous bacterial peritonitis in patients with cirrhosis and ascites...
  69. ncbi request reprint Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial
    George V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 97:2063-70. 2002
    ..The aim of this study was to evaluate whether ursodeoxycholic acid (UDCA) has any effect on the development of liver decompensation and on survival of patients with primary biliary cirrhosis (PBC)...
  70. ncbi request reprint Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding
    Nikolaos Sevastos
    Academic Department of Medicine, Hippokration General Hospital, 114 Vas Sofias Ave, 11527 Athens, Greece
    Eur J Gastroenterol Hepatol 14:797-800. 2002
    ..In addition to the usual resuscitation measures, the patient was treated with primary repair of the small-intestine defect and replacement of the aneurysm with a prosthetic aortic graft. He remains in excellent health thereafter...
  71. ncbi request reprint MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis
    George V Papatheodoridis
    2nd Department of Internal Medicine, National University of Medical School, Hippokration General Hospital, 114 Vas Sophias Ave, 115 27 Athens, Greece
    World J Gastroenterol 11:3099-104. 2005
    ..We compared the predictive values of MELD, Child-Pugh and creatinine-modified Child-Pugh scores in decompensated cirrhosis...
  72. ncbi request reprint Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis
    Evangelos Cholongitas
    2nd Department of Internal Medicine, Hippokration General Hospital, Athens University School of Medicine, 115 27 Athens, Greece
    Liver Int 25:57-61. 2005
    ..To evaluate the characteristics and possible recent changes of the microbial causes of spontaneous bacterial peritonitis (SBP) in cirrhotic patients...
  73. ncbi request reprint Precore mutant chronic hepatitis B - approach to management
    Stephanos J Hadziyannis
    Department of Medicine Hepatology, Henry Dunant Hospital, Athens, Greece
    MedGenMed 5:1. 2003
  74. ncbi request reprint Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 11526 Athens, Greece
    Expert Rev Anti Infect Ther 2:475-83. 2004
    ..All these characteristics make adefovir dipivoxil an important drug for the treatment of hepatitis B virus infection and an excellent candidate for long-term maintenance therapy in chronic viral B liver disease...
  75. ncbi request reprint Emerging treatments in chronic hepatitis B
    Stephanos J Hadziyannis
    Henry Dunant Hospital, Department of Medicine and Hepatology, 107 Messogion Avenue, Athens 11526, Greece
    Expert Opin Emerg Drugs 9:207-21. 2004
    ..Long-term maintenance treatment with antiviral agent(s) with good safety and tolerability profiles and low resistance rates appears to be the most realistic future therapeutic option for most chronic hepatitis B patients...
  76. ncbi request reprint Serum HBV-DNA levels in inactive hepatitis B virus carriers
    Emanuel K Manesis
    Gastroenterology 122:2092-3; author reply 2093. 2002
  77. ncbi request reprint Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen-negative chronic hepatitis B virus infection
    George V Papatheodoridis
    Hepatology 46:606-7; author reply 607. 2007
  78. ncbi request reprint HBsAg-negative HBV mutant transfusion-related acute hepatitis B
    Maria Schina
    Am J Gastroenterol 102:216-7. 2007
  79. ncbi request reprint Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation
    Maria Luisa Raimondo
    Liver Transplant and Hepatobiliary Medicine, Royal Free Hospital, London, UK
    Transplantation 75:186-90. 2003
    ..Our experience with MMF in the same setting but with longer follow-up is described...
  80. ncbi request reprint Adipokines and insulin resistance in chronic hepatitis C
    Emmanuel Tsochatzis
    Hepatology 46:2050-1; author reply 2051. 2007
  81. doi request reprint Role of genetic polymorphisms in the progression of liver fibrosis in chronic hepatitis C virus infection
    George V Papatheodoridis
    Liver Int 28:764-6. 2008
  82. ncbi request reprint Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation
    Dimitrios N Samonakis
    Royal Free Hospital, Liver Transplantation and Hepatobiliary Unit, London, UK
    Liver Transpl 11:386-95. 2005
    ..Maintenance azathioprine gave survival advantage...
  83. ncbi request reprint Peginterferon-alpha2a (40 kDa) for chronic hepatitis C
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Ave, 11526 Athens, Greece
    Expert Opin Pharmacother 4:541-51. 2003
    ..PEG-IFN-alpha(2a) (40 kDa) is expected to improve the efficacy and tolerability of treatment for chronic hepatitis C...
  84. doi request reprint Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation
    Evangelos Cholongitas
    Liver Transplantation and Hepatobiliary Unit, Royal Free Hospital, London, UK
    Liver Transpl 14:138-43. 2008
    ..025). In conclusion, the presence of UC post-LT, and the need for maintenance steroids post-LT, which is an independent factor, are associated with rPSC. These findings could help elucidate a possible mechanism of PSC pathogenesis...
  85. ncbi request reprint Ursodeoxycholic acid and histological progression in primary biliary cirrhosis
    Chun Wing Chan
    J Hepatol 39:1094-5. 2003